For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Royalty Pharma plc (RPRX) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-10-08): Designation Low · Gem Score -37 (−100…+100 Quality+Value blend) · Quality -3 · Value -59 · Sentiment 36 (timing only, not weighted) · Composite fair value $16.74 vs $62.07 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Royalty Pharma plc
RPRX NASDAQRoyalty Pharma plc is the world's largest buyer of biopharmaceutical royalties and a leading funder of innovation in the life sciences sector. The company acquires royalties entitling it to payments based on net sales of approved therapies and development-stage product candidates, partnering with innovators from academic institutions, research hospitals, nonprofits, small and mid-cap biotechnology firms, and major global pharmaceutical companies. Its extensive portfolio encompasses royalties on more than 35 commercial products addressing conditions such as cystic fibrosis (e.g., Vertex's Trikafta and Kalydeco), multiple sclerosis (e.g., Biogen's Tysabri and Spinraza), blood cancers (e.g., Imbruvica from AbbVie and Johnson & Johnson), prostate cancer (e.g., Xtandi from Astellas and Pfizer), ATTR amyloidosis (e.g., Alnylam's Amvuttra), and schizophrenia (e.g., Bristol Myers Squibb's Cobenfy), alongside over 20 pipeline assets targeting vitiligo, Hunter syndrome, lupus, hereditary angioedema, and cardiovascular disease. Royalty Pharma plc provides tailored non-dilutive funding solutions to support late-stage clinical trials and product launches, holding a dominant position with significant global market share in biopharma royalty transactions. Founded in 1996 and headquartered in New York, NY, it operates at the intersection of science, medicine, and investing to accelerate bio-innovation.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 1.78
Total Equity: $9.71B
Shares: 564,455,000
Total Debt: $8.95B
Cash: $618.70M
EBITDA: $1.56B
Total Debt: $8.95B
Cash: $618.70M
Revenue: $2.38B
Revenue: $2.38B
Revenue: $2.38B
Total Equity: $9.71B
Tax Rate: 0.0%
Equity: $9.71B
Total Debt: $8.95B
Cash: $618.70M
Current Liabilities: $636.21M
Long-Term Debt: $8.57B
Total Debt: $8.95B
Total Equity: $9.71B
Shares: 564,455,000
Shares: 564,455,000
CapEx: $0.00
Shares: 564,455,000
Stock Price: $61.33
Net Income: $770.95M
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 26, 2026 1:01am (43d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $2.3B | $2.2B | $2.4B | $2.3B | $2.4B |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | $858.7M | $1.9B | $862.4M | $971.1M | $818.7M |
| Operating Income | $1.4B | $307.1M | $1.5B | $1.3B | $1.6B |
| Net Income | $619.7M | $42.8M | $1.1B | $859.0M | $770.9M |
| EBITDA | — | — | $1.5B | $1.3B | $1.6B |
| EPS | $1.49 | $0.10 | $2.54 | $1.92 | $1.79 |
| EPS (Diluted) | $1.49 | $0.10 | $2.53 | $1.91 | $1.78 |
Balance Sheet (Annual)
Last updated: Aug 26, 2026 12:30am (43d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $1.5B | $1.7B | $477.0M | $929.0M | $618.7M |
| Total Current Assets | $2.9B | $2.6B | $1.3B | $1.8B | $1.5B |
| Total Assets | $17.5B | $16.8B | $16.4B | $18.2B | $19.6B |
| Current Liabilities | $171.3M | $1.2B | $161.4M | $1.3B | $636.2M |
| Long-Term Debt | $7.1B | $6.1B | $6.1B | $6.6B | $8.6B |
| Total Liabilities | $7.3B | $7.3B | $6.3B | $7.9B | $9.9B |
| Total Equity | $10.2B | $9.5B | $10.1B | $10.3B | $9.7B |
| Retained Earnings | $2.3B | $2.0B | $2.5B | $2.8B | $2.4B |
Cash Flow (Annual)
Last updated: Aug 26, 2026 1:01am (43d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $2.0B | $2.1B | $3.0B | $2.8B | $2.5B |
| Capital Expenditure | — | — | — | — | — |
| Free Cash Flow | — | — | — | — | — |
| Acquisitions (net) | — | — | $0 | $0 | -$74.4M |
| Net Debt Issued / (Repaid) | $1.3B | $0 | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | -$304.8M | -$229.7M | -$1.2B |
| Net Change in Cash | $532.4M | $169.7M | -$1.2B | $452.0M | -$310.3M |
Growth Trends (YoY %)
Last updated: Aug 26, 2026 1:01am (43d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -2.3% | +5.2% | -3.9% | +5.1% |
| Gross Profit Growth | — | — | — | — |
| Operating Income Growth | -78.5% | +385.9% | -13.4% | +20.7% |
| Net Income Growth | -93.1% | +2,549.5% | -24.3% | -10.2% |
| EBITDA Growth | — | — | -13.4% | +21.0% |
Dividend History (Last 20)
Last updated: Aug 25, 2026 7:38am (43d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-08-14 | $0.24 | — | — | — |
| 2026-05-15 | $0.24 | — | — | — |
| 2026-02-20 | $0.24 | — | — | — |
| 2025-11-14 | $0.22 | — | — | — |
| 2025-08-15 | $0.22 | — | — | — |
| 2025-05-16 | $0.22 | — | — | — |
| 2025-02-21 | $0.22 | — | — | — |
| 2024-11-15 | $0.21 | — | — | — |
| 2024-08-16 | $0.21 | — | — | — |
| 2024-05-16 | $0.21 | — | — | — |
| 2024-02-15 | $0.21 | — | — | — |
| 2023-11-16 | $0.20 | — | — | — |
| 2023-08-17 | $0.20 | — | — | — |
| 2023-05-18 | $0.20 | — | — | — |
| 2023-02-15 | $0.20 | — | — | — |
| 2022-11-17 | $0.19 | — | — | — |
| 2022-08-18 | $0.19 | — | — | — |
| 2022-05-19 | $0.19 | — | — | — |
| 2022-02-17 | $0.19 | — | — | — |
| 2021-11-18 | $0.17 | — | — | — |
Deep Analysis
Risk : Reward — upside vs downside from this company's own quarters
Computed 2026-10-07 02:03A +1σ run of quarters pays -55%; a −1σ run costs 84%. Ratio -0.7:1 (μ 7.3%, σ 7.8% , 16 pairs).
Older method (repeat-worst-quarter): -0.6 : 1
| Case | Growth | Margin | Fair value | vs price ($62.07) |
|---|---|---|---|---|
| Bull — recovery | +16% | 35.0% | $31.68 | -49% |
| Base — stabilizes | +11% | 32.0% | $24.63 | -60% |
| Bear — keeps slipping | +5% | 27.2% | $17.87 | -71% |
| Stress — last quarter repeats | +8% | 17.2% | $12.98 | -79% |
| Upside — a +1σ run of quarters (v2) | +15% | 32.2% | $28.19 | -55% |
| Stress — a −1σ run of quarters (v2) | -1% | 17.0% | $9.83 | -84% |
Narrative Economics
market-narrative step).
Growth Outlook
Analyzed 2026-08-26 01:10The question every valuation on this page silently assumes: is this company likely to grow? Judged forward — the business, its category, the world — against what's already printed.
Claude Reading
Looking at the raw numbers first: RPRX prints ~$2.4B in annual revenue growing at a glacial 0.5% CAGR over five years (2021: $2.29B → 2025: $2.38B), while operating cash flow is a very real $2.49B on $35.4B market cap — that's a ~7% OCF yield, not a growth story. The quarterly trajectory actually shows acceleration in 2025-2026: $568M → $579M → $609M → $622M → $631M → $674M, roughly 8-10% YoY, which is a genuine inflection from the flat 2021-2024 baseline. Net income is wildly lumpy (Q2'26 at $17.9M vs Q1'26 at $294.7M — 2.7% vs 46.7% margins), which reflects mark-to-market on royalty financial instruments, not operating deterioration. The balance sheet carries $8.95B debt against $9.71B equity and $2.49B OCF — leverage is meaningful (0.92 D/E, ~3.6x debt/OCF) but serviceable for an annuity-like cash flow business. Insider activity is a mix of routine awards and small sales/gifts — genuinely neutral, not a tell.
The synthesis verdict of $17 fair value (-73%) is almost certainly wrong and I dissent hard. A DCF spitting out $17 on a company generating $2.49B of operating cash flow against a $35B cap implies either a punitive discount rate, terminal decline assumption, or treating royalty amortization as real economic cost. It's the third — RPRX's GAAP earnings dramatically understate cash economics because acquired royalty intangibles amortize against income while cash keeps flowing. The pre-flight note catches this correctly (34x P/E vs 14x P/FCF gap), but then the valuation synthesis ignores its own insight. At 14x FCF with 5% recent revenue growth, ~1.5% dividend, and ~$8-9B in remaining royalty duration on the existing book, fair value is plausibly $55-70, not $17. The Market Forces "deteriorating asset in value-destructive cycle" claim is contradicted by the quarterly acceleration — Q2'26 revenue of $674M annualizes to $2.7B, up ~13% from 2024's $2.26B.
That said, the bear case in the narrative layer has real teeth and I won't dismiss it. RPRX has no moat — any well-capitalized buyer can bid for royalties, and the deal environment matters enormously. The $8.95B debt load was accumulated to fund acquisitions during cheap-money years; refinancing at higher rates compresses spread economics. ROIC of 8.6% against a cost of capital that's arguably 7-8% in current rates leaves razor-thin excess return on new deployment. If management pays up for a couple of bad royalty streams (Trelegy, Trodelvy, cystinuria assets that disappoint), the whole "compounder" thesis unravels. The contrarian argument is that this is a leveraged bond fund dressed as a growth compounder, and 14x FCF is a fair — not cheap — multiple for a mature, competitively-exposed royalty aggregator with mid-single-digit organic growth. A skeptic would anchor closer to 10-11x FCF, or roughly $45-50.
Net: I dissent from the -73% overvalued call — the composite is broken by amortization-driven GAAP distortion. I'm also skeptical of table-pounding bull cases; the narrative layer's "fragile durability" flag is well-earned. My read is fairly valued to modestly undervalued in the $55-65 range with real optionality if the 2026 revenue acceleration (13% YoY) proves durable rather than a lumpy royalty-timing artifact. At $61.33 the setup is roughly balanced: 7% cash yield + 1.5% dividend + low-to-mid single digit growth = 10-12% expected return if the acquisition engine keeps working, meaningfully less if deal spreads compress. I wouldn't chase, but the synthesis "sell everything, worth $17" verdict is a modeling error, not a thesis.
GPT Reading
Royalty Pharma’s raw numbers look far better than the most bearish model outputs suggest, but they also do not support paying an “infrastructure-like” premium at $61. The central fact is that this is a cash generative royalty portfolio with remarkably stable top-line performance: annual revenue has sat in a narrow $2.24B-$2.38B band for four years, and the quarterly run-rate has climbed from $564.7M in 2024-09 to $674.1M in 2026-06. That is not a deteriorating business. The latest two quarters sum to $1.30B, up about 10% versus the comparable 2025 first half of $1.15B, so near-term revenue momentum is actually decent. Operating profitability is also consistently high at a 65.6% operating margin in 2025, with $1.56B of operating income on $2.38B of revenue. Most importantly, operating cash flow was $2.49B in 2025 against net income of $770.9M, which tells you the accounting optics are heavily burdened by non-cash charges; a 34.5x P/E is overstating economic expensiveness for this kind of asset-heavy royalty model.
That said, the equity is still hard to call cheap because the market cap is $35.4B against a business whose growth has been modest and whose balance sheet is meaningfully levered. Using 2025 operating cash flow, the stock trades around 14.2x OCF, not insane for a durable healthcare cash-flow stream but not a bargain either, especially with $8.95B of debt and only $618.7M of cash. Enterprise value is roughly $43.8B, which aligns with the cited 22.2x EV/EBITDA and 14.6x EV/revenue multiples—full prices for a company with roughly 0.5% revenue CAGR over the measured period. Net income volatility is another clue that this is not a simple annuity deserving utility-like valuation: quarterly margins swung from 2.7% in 2026-06 to 46.7% in 2026-03, and from 5.6% in 2025-06 to 47.3% in 2025-09. Even if some of that is mark-to-market or amortization noise, investors are still paying up for a portfolio that has to be continuously replenished through dealmaking, often with debt, in a competitive market for royalty assets.
The biggest disconnect in the provided models is the DCF-style fair value in the mid-teens. That looks too low given the actual cash coming off this platform. A company producing $2.49B of operating cash flow and over $600M of quarterly revenue is not plausibly worth only $16 per share unless one assumes dramatic runoff, value-destructive capital allocation, or a severe collapse in future royalty receipts. The historical revenue line does not show that collapse. Nor do I buy the strongest bear formulation that this is plainly “deteriorating”: 2022 was the obvious outlier with just $42.8M of net income and $307.1M of operating income, but results rebounded sharply in 2023-2025, and 2026 revenue is tracking ahead of prior periods. This is a real business with real cash earnings power. The problem is less solvency or franchise decay than valuation discipline: the stock is priced as if stable cash flow plus moderate deal-driven growth deserve a premium multiple indefinitely.
The strongest counterargument to my caution is that this company may deserve that premium because its accounting earnings dramatically understate owner economics. If one treats 2025 OCF of $2.49B as the true earnings base and assumes minimal capex, then the equity’s cash yield is around 7%, which is attractive for a healthcare-linked asset base with diversification across many therapies. The current ratio of 2.4 suggests no near-term liquidity stress, debt-to-equity of 0.92 is material but manageable, and the latest revenue trend is better than the long-run CAGR implies. A bull would also point out that 2026 first-half net income of $312.6M was depressed by the weak June quarter; if that quarter reflects one-offs rather than economics, normalized earnings could look much stronger. I weigh that argument seriously, but the answer is not to ignore valuation multiples altogether. A 14.6x sales multiple and 22.2x EV/EBITDA leave little margin for error when the growth algorithm depends on finding new royalty deals at attractive returns.
What would change my mind is evidence that the business has shifted from stable to genuinely compounding. If annual revenue can move convincingly above $2.6B while maintaining operating income north of $1.6B and operating cash flow above $2.5B without debt ballooning past the current $8.95B, then the current price would look more justified and I would lean constructive. Conversely, if the next few quarters show revenue slipping back toward the $580M-$610M range or another stretch of single-digit net margins like 2025-06 and 2026-06, that would confirm the market is overpaying for a lumpier stream than advertised. For now, I see a solid cash machine, not a broken one—but also not one that should command a heroic premium.
Grok Reading
The raw numbers paint Royalty Pharma as a high-margin cash collector whose top line has barely moved for half a decade. Annual revenue crawled from $2.29B in 2021 to $2.38B in 2025—a 0.5% CAGR—while recent quarterly run-rate finally shows modest lift ($568M → $674M over six quarters, ~5% YoY). Operating cash flow of $2.49B on that base is the real story: nearly all of it drops through because this is an asset-light royalty aggregator with negligible capex. Operating margin sits at 66% and net margin 32%, yet reported net income has eroded from $1.13B in 2023 to $771M in 2025 (earnings CAGR –17.6%) as amortization of acquired royalty intangibles and deal costs distort the P&L. Returns are pedestrian—ROE 7.9%, ROIC 8.6%, ROA 3.9%—on a balance sheet carrying $8.95B of debt against only $619M cash and $9.71B equity (D/E 0.92). At $61.33 the stock trades 34.5× earnings, 14.6× sales, 22× EV/EBITDA and roughly 14× operating cash flow; a 1.5% dividend yield does not compensate. The market is paying a premium multiple for a mature, low-organic-growth annuity whose incremental returns on new capital have yet to prove accretive enough to justify the price.
What stands out is the disconnect between cash generation quality and capital efficiency. The $2.49B OCF is durable and recession-resistant so long as the underlying drug royalties hold, which explains why the stock can trade near highs even as earnings and FCF CAGRs print negative. But ROIC below 9% while levering up to chase new royalties is the classic mature-earner trap: you are buying yesterday’s high-margin streams and diluting them with tomorrow’s more expensive ones. Quarterly net margins swinging from 2.7% to 47% underscore how little the GAAP line tells you; investors should anchor on cash, and even on cash the equity is priced for perfection.
The strongest counter-argument is that the $16–17 composite fair value from the quantitative stack is unrealistically punitive. Capitalizing $2.49B of operating cash flow at an 8% required return already implies ~$31B of enterprise value before any growth optionality or portfolio duration; add the visible 5% recent revenue acceleration, expanding absolute operating income ($1.29B → $1.56B), and the structural scarcity of large-scale royalty portfolios, and a mid-teens free-cash-flow multiple is defensible for a quasi-utility with pharma upside. Bulls will correctly note that any buyer can theoretically bid for royalties, yet few have RPRX’s scale, tax structure, or permanent capital, so the “no moat” claim is overstated. If management continues to layer on mid-single-digit revenue growth via acquisitions without destroying ROIC, the 280% gap to the model DCF simply reflects that the model underweights duration and optionality.
I would flip to neutral or constructive only if the next two years deliver sustained revenue growth above 8–10% with ROIC reclaiming double digits, or if a major new blockbuster royalty (multi-hundred-million annual contribution) is announced at a clear spread to cost of capital while net leverage stays below 3×. Conversely, two consecutive quarters of sequential revenue decline or a large dilutive deal that pushes ROIC under 7% would confirm the overvaluation thesis and open downside toward the mid-$40s.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
Royalty Pharma is a mature earner producing genuinely high-quality cash: FCF has run $2.0B-$3.0B every year 2021-2025 ($2.49B in 2025) against revenue of only $2.26B-$2.38B, and OCF/NI of 12.5x with accruals at -10.2% of assets confirms the earnings are more than backed by cash. Operating margin sits at 65.6% in 2025 (2022's 13.7% dip reflects the royalty-accounting quirks of the model, not operational failure). This is a business that structurally converts revenue to cash at exceptional rates and does not need external capital to operate.
Verify before trusting this (5)
- Concentration risk: what % of royalties come from the top 3-5 drugs and their patent expiry dates
- Terms of the internalization transaction with the external manager (drove SBC/share issuance surge)
- Debt maturity ladder and covenants against the $8.33B net debt position
- Pace and IRR of new royalty acquisitions - is the portfolio being replenished faster than it runs off
- Whether 2022's op margin collapse to 13.7% was a one-time non-cash write-down or something recurring
The e2e composite fair value of $17.31 and signal-adjusted $16.32 imply -73% downside from $62.07 - a gap so wide it almost certainly reflects an EPV floor that treats a growing royalty aggregator as a static, no-reinvestment cash annuity. I discount the literal number: an 8% share count CAGR funds royalty acquisitions that do add value, so pure EPV understates deserved value. That said, even generously capitalizing current FCF and giving credit for the acquisition engine, the $35B market cap requires the royalty portfolio to keep compounding on a mature, generic-exposed base - which is exactly the bear case.
Verify before trusting this (4)
- Incremental royalty acquisition IRRs vs cost of capital in latest 10-Q
- Guidance on receipts growth ex-acquisitions to isolate organic vs bolt-on contribution
- Generic/LOE exposure schedule across top 5 royalties over next 5 years
- Pace and pricing of share issuance and any buyback offset
The tape is mildly risk-on and RPRX just printed a 52-week high on the back of Ziihera's FDA approval feeding directly into its royalty book. That is exactly the kind of concrete, on-narrative catalyst that reinforces the 'platform-monopoly / diversified cash-flow moat' story the market is paying a premium for. Momentum, which had been quietly negative, gets a jolt of validation from a headline that literally names the ticker alongside Merck as a winner. With a beta of 0.43, the modest S&P pullback and elevated 10y at 4.7% barely graze this name; if anything, a nervy tape rewards the 'quasi-utility with pharma upside' framing. The narrative is flagged as strong but fragile - it works while deals and approvals keep landing, and today one did. Analyst tone isn't shown, but price action making new highs into a soft tape is itself a tell of positive positioning. Net: non-fundamental pressure is pushing up right now. The risk is durability - a single missed acquisition cycle or a generic scare can snap a fragile story - but that's a watch item, not today's force.
Verify before trusting this (4)
- Whether the Ziihera pop holds for more than a session or fades as a one-day headline
- Analyst target revisions following the approval - upgrades would extend the tailwind
- Next acquisition announcement cadence - a dry spell would crack the fragile narrative
- Any move in the 10y above 5% that would pressure long-duration cash-flow names
The world is producing more approved biopharma innovation than small-cap balance sheets and a 4.7% cost of capital can finance — that is the structural supply of royalty sellers, and RPRX is the largest, most credible buyer. Higher rates cut both ways: they raise RPRX's discount rate but also raise the price innovators pay for non-dilutive capital, widening the spread RPRX can demand. Policy risk to US drug pricing is the real systemic threat, since receipts are a percentage of net sales; broad price concessions would hit every stream simultaneously. Against that, an aging population and durable specialty-drug volume growth keep the underlying base expanding.
When we made this prediction on Aug 26, 2026, RPRX was $62.07. We expect it to be $52.00 by Feb 2027, and we consider it great value under $45.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Aug 26, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.